- Opinion
- [Reporter's view]Is the Drug Price Reduction Act Good?
- by Kim, Jin-Gu Mar 6, 2023 05:56am
- The fate of the so-called drug price reduction/refund law will be decided sooner or later. It is expected that a decision will be made within this month at the earliest, whether it will be possible to limit the tricks of avoiding drug price cuts for original drugs for several years by applying for suspension of execution. The amendment to the
- Opinion
- [Reporter's view] Implications of Lucentis biosimilar
- by Lee, Tak-Sun Feb 27, 2023 05:57am
- The domestic prescription drug market is not a market where prices can operate with competitiveness. This is because paying patients do not have the option to choose a product, and doctors who have the option do not have a margin on sales of insurance drugs, so there is little incentive to prescribe low-priced products. Because of this, even
- Opinion
- [Reporter’s View] Decide whether to offer free HCV testing
- by Jung, Sae-Im Feb 24, 2023 05:53am
- Eight years have passed since discussions began on adding hepatitis C (HCV) screening as a free item in Korea’s national health examination program. Despite various supporting evidence that was produced during the period, including the feasibility study that started in 2016, and an analysis that showed that it was cost-effective to include
- Opinion
- [Reporter's view] An uncomfortable gift from the gov
- by Kim, Jin-Gu Feb 17, 2023 05:50am
- The Ministry of Trade, Industry and Energy is pushing to designate key technologies used in the development of biopharmaceuticals as "national high-tech strategic technologies." If bio-core technology is designated as a state-of-the-art strategic technology, various benefits will follow. They include support for the creation of specialized co
- Opinion
- [Reporter's view]National Security & the Price Policy
- by Lee, Jeong-Hwan Feb 16, 2023 05:52am
- Second Vice Minister of Health and Welfare Park Min-soo reaffirmed that the pharmaceutical bio-industry is directly related to national security and expressed his belief to support the pharmaceutical bio-industry by reorganizing the drug price system. It said it will give some form of benefit to pharmaceutical companies that make medicines us
- Opinion
- [Reporter’s View] Asthma drugs await reimb discussions
- by Eo, Yun-Ho Feb 14, 2023 05:48am
- The asthma drugs that had long remained unreimbursed since their approval has resurfaced at the table for discussions, but the situation has not improved much from before. The government and the companies are seemingly unable to reach a consensus on the appropriate drug price. Three asthma biological drugs that were developed at similar
- Opinion
- [Reporter’s View] Improving NHI-related legislation
- by Lee, Jeong-Hwan Feb 6, 2023 05:51am
- The bill to remove the administrative drug price cut and reimbursement suspension dispositions that were imposed on illegal drug rebates from the current National Health Insurance Act and raising the penalty surcharge system has drawn industry attention and rose as an issue of focus this year. The bill aims to minimize third-party damage
- Opinion
- [Reporter's view] Leader's responsibility
- by Feb 3, 2023 05:53am
- One of the common grievances faced by employees of Korean subsidiaries of foreign companies is "Leader's irresponsibility." The representative of a Korean corporation is the head of a company in Korea, but he is one of the branch managers of many countries in the global view. Whether you like it or not, you have to follow the instructions of
- Opinion
- [Reporter’s View] CDDC continues to raise controversy
- by Eo, Yun-Ho Feb 1, 2023 05:54am
- The Cancer Disease Deliberation Committee has settled as the highest threshold in reimbursement for anticancer drugs in Korea. This expert committee, which is a mandatory step for reimbursement in Korea, has put many anticancer drugs through an ordeal, to the extent that it was coined the ‘wailing wall’ to reimbursement in Korea. The co
- Opinion
- [Reporter's view] There's no instability in supply & demand
- by Lee, Tak-Sun Jan 26, 2023 06:06am
- Last-minute discussions between the NHIS and the pharmaceutical industry are underway regarding PVA of cold medicines, which increased their use due to COVID-19 last year. The consultation began when the government decided to correct the usage instead when the pharmaceutical industry suggested that cold medicines, which have increased their
